Skip to main content

Advertisement

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy

Fig. 2

Treatment of NOTCH1-mutated MCL cells with OMP-52M51 effectively prevents DLL4-dependent activation of Notch1. a Mino and JeKo-1 MCL cells and NOTCH1-mutated primary MCL cells (patient sample MCL) were treated with OMP-52M51 or IgG2 control antibody and stimulated with human recombinant DLL4 (4 μg/mL). Protein expression of cleaved Notch1 was determined by Western Blot analysis after 24 and 48 h. b Mino and JeKo-1 MCL cells were treated with OMP-52M51 and cocultured with DLL4-overexpressing OP9-stromal cells or GFP-transfected control cells. After 48 h, Western Blot analysis of cleaved Notch1 protein expression was performed. c Significantly modulated genes (FDR < 0.123; p < 0.005; NES > 1.48) related to the Notch1 signaling pathway (NOTCH custom) upon stimulation of Mino and JeKo-1 cells with DLL4 after 48 h obtained with the Gene Set Enrichment Analysis (GSEA) software. d Significantly upregulated genes (FDR < 0.001; p < 0.001, NES = 3.00) upon stimulation of Mino and JeKo-1 cells with DLL4 after 48 h obtained with GSEA applying a signature of Notch target genes described in MCL cells (NOTCH direct targets). Heatmaps were hierarchical clustered by one minus Pearson correlation of the average of gene expression

Back to article page